Novartis secures new approval in China for Cosentyx® (secukinumab) in pediatric psoriasis

2021-08-23
Novartis secures new approval in China for Cosentyx® (secukinumab) in pediatric psoriasis

August 17, 2021 –  Novartis today announced that the China National Medical Products Administration (NMPA) has further approved Cosentyx® (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in pediatric patients (six years and older with a body weight ≥50 kg) who are candidates for systemic therapy or phototherapy, making it the only interleukin inhibitor approved in China for these patients. Cosentyx is already approved in China for the treatment of moderate-to-severe plaque on two Phase III international studies in pediatric patients aged 6 to < 18 years old, which showed that Cosentyx was as safe in children and adolescents as when used in adults。


Novartis is committed to making Cosentyx available to young patients who may benefit from the therapy and has recently filed for US and European regulatory approval for Cosentyx as a potential treatment in juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA), two subtypes of juvenile idiopathic arthritis (JIA). Currently, there are very limited approved treatment options for JIA, and only a minority of patients go on to achieve and maintain an inactive disease state.